Policy | January 26, 2022
Mandaviya reviews public health preparedness to Covid-19
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Go-ahead for pivotal clinical trial which is expected to commence by March
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon has reported consolidated financial results for the period ended December 31, 2021
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Subscribe To Our Newsletter & Stay Updated
